A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Participant with body mass index (BMI) ≥18 kilograms per square meter (kg/m\^2).
Participant with symptomatic ALS as diagnosed by Gold Coast diagnostic criteria.
Sporadic ALS cohorts: Negative testing for known monogenic mutations associated with familial ALS.
SOD1-ALS (Cohorts 2 and 3 only): Confirmed pathogenic SOD1 mutation, with negative testing for other genetic mutations associated with familial ALS.
Any polymorphism or mutation in the coding region will require additional review by the Sponsor to determine compatibility with the study intervention.
Baseline ALSFRS-R ≥ 24.
ALS disease duration ≤ 42 months.
You may not be if
Previous treatment for ALS with cellular or gene therapies.
Any investigational medication or treatment (for ALS or other condition).
